Comparative Pharmacology
Head-to-head clinical analysis: INREBIC versus RUXOLITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INREBIC versus RUXOLITINIB.
INREBIC vs Ruxolitinib
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor. It inhibits JAK2 and its mutant forms, including JAK2V617F, leading to reduced phosphorylation of signal transducer and activator of transcription (STAT) proteins and decreased proliferation of abnormal hematopoietic cells.
Selective inhibitor of Janus-associated kinases (JAK) JAK1 and JAK2, reducing cytokine signaling and hematopoiesis.
100 mg orally twice daily continuously until disease progression or unacceptable toxicity.
Myelofibrosis: 5-25 mg orally twice daily based on platelet count; Polycythemia Vera: 10 mg orally twice daily; Graft-versus-Host Disease: 5-10 mg orally twice daily.
None Documented
None Documented
Clinical Note
moderateRuxolitinib + Digoxin
"Ruxolitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRuxolitinib + Digitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRuxolitinib + Deslanoside
"Ruxolitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRuxolitinib + Acetyldigitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 14 hours; supports twice-daily dosing for steady-state attainment within 3 days
The terminal elimination half-life of ruxolitinib is approximately 3 hours for the parent drug. However, the pharmacodynamic half-life for JAK2 inhibition is longer (up to 8-12 hours) due to sustained target suppression.
Fecal (77.6% as metabolites, 2.2% as unchanged drug); renal (8.5% as metabolites, <1% as unchanged drug)
Ruxolitinib is primarily metabolized in the liver, and its metabolites are excreted renally. Approximately 74% of the dose is eliminated in urine (mainly as metabolites) and 22% in feces (as unchanged drug and metabolites).
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor